T
Thomas F. Lüscher
Researcher at University of Zurich
Publications - 1613
Citations - 88517
Thomas F. Lüscher is an academic researcher from University of Zurich. The author has contributed to research in topics: Endothelium & Myocardial infarction. The author has an hindex of 134, co-authored 1560 publications receiving 79034 citations. Previous affiliations of Thomas F. Lüscher include University of Texas Southwestern Medical Center & Durham University.
Papers
More filters
Journal ArticleDOI
Comparative Pharmacological Properties among Calcium Channel Blockers: T-Channel versus L-Channel Blockade
Georg Noll,Thomas F. Lüscher +1 more
TL;DR: Mibefradil is a new calcium antagonist with promising pharmacological and clinical properties, which represents a new class of calcium channel blockers in patients with hypertension and is a particularly efficacious vasodilator in intramyocardial coronary arteries.
Journal ArticleDOI
2014 ESC/ESA Guidelines on Non-cardiac Surgery: Cardiovascular Assessment and Management
Steen Dalby Kristensen,Juhani Knuuti,Antti Saraste,Stefan D. Anker,Hans Erik Bøtker,Stefan De Hert,Ian Ford,José Ramón González-Juanatey,Bulent Gorenek,Guy R. Heyndrickx,Andreas Hoeft,Kurt Huber,Bernard Iung,Keld Kjeldsen,Dan Longrois,Thomas F. Lüscher,Luc Pierard,Stuart J. Pocock,Susanna Price,Marco Roffi,Per Anton Sirnes,Miguel Sousa-Uva,Vasilis Voudris,Christian Funck-Brentano +23 more
Journal ArticleDOI
Electrophysiological findings in patients with isolated left ventricular non-compaction.
Jan Steffel,Richard Kobza,Mehdi Namdar,Thomas Wolber,Corinna Brunckhorst,Thomas F. Lüscher,Rolf Jenni,Firat Duru +7 more
TL;DR: Ventric and supraventricular arrhythmias can readily be induced in patients with isolated left ventricular non-compaction, whereas the inducibility of a sustained monomorphic VT is relatively low.
Journal ArticleDOI
Cholesterylestertransfer protein inhibition and endothelial function in type II hyperlipidemia
Frank Hermann,Frank Enseleit,Lukas E. Spieker,Daniel Périat,Isabella Sudano,Matthias Hermann,Roberto Corti,Georg Noll,Frank Ruschitzka,Thomas F. Lüscher +9 more
TL;DR: In patients with type II hyperlipidemia, CETP inhibition with JTT-705 increased HDL-C and lowered triglycerides but improved endothelial function in the subgroup of patients with low baseline HDL- C levels only.
Journal ArticleDOI
Interplay among H3K9-editing enzymes SUV39H1, JMJD2C and SRC-1 drives p66Shc transcription and vascular oxidative stress in obesity.
Sarah Costantino,Sarah Costantino,Francesco Paneni,Francesco Paneni,Agostino Virdis,Shafaat Hussain,Shafeeq A. Mohammed,Shafeeq A. Mohammed,Giuliana Capretti,Alexander Akhmedov,Kevin Dalgaard,Sergio Chiandotto,J. Andrew Pospisilik,Thomas Jenuwein,Marco Giorgio,Massimo Volpe,Stefano Taddei,Thomas F. Lüscher,Francesco Cosentino +18 more
TL;DR: It is shown that SUV39H1 is the upstream effector orchestrating JMJD2C/SRC-1 recruitment to p66Shc promoter, which may attenuate oxidative transcriptional programmes and thus prevent vascular disease in obese individuals.